Biohaven Ltd. has acquired global rights, excluding China regions, from Hangzhou Highlightll Pharmaceutical Co. Ltd. for TLL-041, now designated BHV-8000, an oral, brain-penetrant, highly selective, dual TYK2/JAK1 inhibitor, for neurological disorders.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by failure of motor neurons that lead to paralysis. To date, no treatment exists for ALS that focuses on improving neuromuscular transmission, which would improve quality of life for ALS patients.
Hangzhou Healzen Therapeutics Co. Ltd. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, among others.
Artivila Therapeutics (Shenzhen) Co. Ltd. has identified NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of Alzheimer's and Parkinson's diseases, multiple sclerosis, amyotrophic lateral sclerosis and peripheral neuropathy.
Nurexone Biologic Inc. has released further results from a preclinical study of Exopten demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.
The neuron-specific K+/Cl- co-transporter KCC2 is involved in the shift from depolarizing to hyperpolarizing γ-aminobutyric acid receptor (GABAAR) currents and subsequent synaptic inhibition.
Investigators from the Thomas Jefferson University have presented a case report of a 27-year-old pregnant patient in whom cystic hygroma, extensive anasarca, bilateral pleural effusions, ascites, abnormally curved sacrum and hydrocephalus with parenchymal volume loss, among others were detected by prenatal imaging during pregnancy (onset was at about 21 weeks of gestation).